ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Oncternal gets FDA orphan drug designations for cirmtuzumab to treat MCL and CLL
July 06, 2020Oncternal Therapeutics announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designations of cirmtuzumab for treatment of mantle cell lymphoma (MCL) and for treatment of chronic lymphocytic leukaemia ... -
Oncternal Announces First Patient Dosed in Cirmtuzumab, Paclitaxel Trial
September 13, 2018Oncternal Therapeutics announced the first patient has been dosed in a Phase 1b study of cirmtuzumab, an anti-ROR1 monoclonal, in combination with standard-of-care chemotherapy drug paclitaxel in patients with HER2/neu negative metastatic or locally advan
Pharma Sources Insight January 2025
